[Commentary on] A US Policy Perspective on Oral Preexposure Prophylaxis for HIV.

• Autores: Arleen A. Leibowitz, Karen Byrnes Parker, Mary Jane Rotheram-Borus
• Localización: American journal of public health, ISSN 0090-0036, Vol. 101, Nº. 6, 2011, págs. 982-985
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Orally administered pre-exposure prophylaxis is an innovative and controversial HIV prevention strategy involving the regular use of antiretroviral medications by uninfected individuals. Antiretroviral medications protect against potential HIV infection by reducing susceptibility to the virus. Recent clinical trial results indicate that pre-exposure prophylaxis can be safe and efficacious for men who have sexual intercourse with men, yet there remain policy considerations surrounding costs, opportunity costs, and ethical issues that must be addressed before broad implementation in the United States. Resources for HIV prevention are limited, thus cost effectiveness analyses of PrEP implementation in non-experimental situations are needed to allocate prevention funding most productively. Findings from the randomized clinical trials that PrEP is efficacious should mark the beginning of the policy discussion, not its end. [ABSTRACT FROM AUTHOR]